Treatments · Entity Annotation Prototype (beta)

6articles mentioning treatments

20treatment mentions

1distinct treatments extracted

0%of mentions human-reviewed

Active filtersEntity: SOC ×

SOC

This treatment is selected. Its supporting articles are shown below.

SOC6

Articles mentioning SOC

6 articles · page 1 of 1

Multiarm multistage randomised controlled trial of inflammatory signal inhibitors (MATIS) for patients hospitalised with COVID-19 pneumonia during the UK pandemic

bmjopen · abstract · 2026-02-05 · 8 matching annotations

82.2%

SOC COVID-19 pneumonia ruxolitinib COVID-19 fostamatinib RUX

…per day for 7 days then 100 mg two times per day for 7 days) or SOC.Main outcome measures Primary outcome was development of severe…

Using real-world data to predict findings of an ongoing phase IV trial: glycemic control of semaglutide versus standard of care

bmjdrc · full text · 2025-10-29 · 6 matching annotations

83.2%

SoC SoC standard of care semaglutide type two diabetes mellitus T2DM end-stage renal disease

…imbursed, regardless of whether they were in the semaglutide or SoC group.15 However, in our study, patients were responsible for t…

O-031 Trufill n-BCA liquid embolic system for middle meningeal artery embolization in subdural hematoma: MEMBRANE study 12-month outcomes

neurintsurg · abstract · 2026-07-19 · 2 matching annotations

75.6%

SOC Balt Group Silk Road Medical TRUFILL n-BCA National Center for Advancing Translational Sciences Miami Clinical and Translational Science Institute cSDH Medtronic Integra LifeSciences TRUFILL n-Butyl Cyanoacrylate+2 more

…cumulative incidence rate [90% CI] of 6.1% [3.8%, 9.9%] in MMAE+SOC and 3.2% [1.6%, 6.2%] in SOC alone at 12 months. KM analysis of…

A101 Middle meningeal artery embolisation for treatment of chronic subdural hematoma (cSDH) with trufill n-BCA: membrane trial primary results

neurintsurg · abstract · 2025-09-02 · 2 matching annotations

80.5%

SOC cSDH Miami Clinical and Translational Science Institute National Center for Advancing Translational Sciences eMMA Mount Sinai TRUFILL n-BCA National Institute on Minority Health and Health Disparities NIH

…alth economic outcomes generally favoured eMMA treatment versus SOC alone.Conclusion This study demonstrates a positive treatment e…

PO:07:179 Benchmark-SLE: prospective observational study of standard of care efficacy and safety in active SLE with inadequate response to glucocorticoids and at least 2 immunosuppressants

lupusscimed · abstract · 2026-03-01 · 1 matching annotations

80.5%

SoC Systemic lupus erythematosus SLE Benchmark-SLE GC lupus nephritis glucocorticoids CA0611025 NCT07175285

…mark-SLE, CA0611025, NCT07175285) will evaluate the efficacy of SoC in achieving remission and improving clinical outcomes in patie…

Cost-effectiveness of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis in Belarus, Georgia, Kazakhstan and the Republic of Moldova

bmjgh · abstract · 2025-11-08 · 1 matching annotations

79.7%

mSTR SOC WHO MDR-TB multidrug-resistant tuberculosis

…ational TB budgets, respectively.Conclusions Compared with SOC, mSTR is a more cost-effective treatment option for MDR/RR-TB, which …